Clinical Trials Browser

Phase 3 × HER2-Positive Primary Breast Cancer × 30 days × Clear all

NCT04622319 2026-05-15

DESTINY-Breast05

Phase 3 Active not recruiting

1,600 enrolled 1 FDA

HER2-Positive Primary Breast Cancer